Clinical trial

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients

NCT04566432

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

OTHER · Unmapped registry intervention Observation Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2020-07-01

PhaseN/A

Conditions

Lung Neoplasmsverified · MONDO: lung neoplasm

Lung Cancer, Nonsmall Cellcandidate · MONDO: tumor suppressor gene on chromosome 11

Adenocarcinoma of Lungverified · MONDO: lung adenocarcinoma

Squamous Cell Lung Cancerverified · MONDO: squamous cell lung carcinoma

Interventions

ObservationOTHER

Sponsors & collaborators

Geneplus-Beijing Co. Ltd.lead sponsor

Shanghai Chest Hospitalcollaborator

Mapped research locations

ShanghaiChina1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04566432 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.